Nucleoside analogues resistance in the treatment of chronic hepatitis B virus infection

[Guest guest]

Rev Med Interne. 2003 Dec;24(12):786-93.

[Nucleoside analogues resistance in the treatment of chronic hepatitis B

virus infection]

[Article in French]

Halfon P, Pol S, Bourliere M, Courcambeck J, Cacoub P.

Departement de virologie, laboratoire Alphabio, Marseille, France

Subject. - Chronic hepatitis B virus (HBV) infection is usually treated by

interferon alpha. However, a sustained response after stopping treatment is

only obtained in 30% of patients.Actuality. - New therapeutic nucleosid

analogs have been developped, i.e. lamivudine, famciclovir, adefovir,

entecavir, clevudine. However, as in HIV infection, clearance of the

original hepatitis B virus with emergence of distinct resistant mutants have

been observed during or after treatment with most nucleosid analogs. In this

review, the underlying mechanisms of resistance and the characterisation of

HBV mutants are described to optimize the best therapeutic

regimen.Perspectives. - Treatment of chronic HBV infection, as most of other

chronic viral infection, should be based on combination therapy with a

special search for the appearance of HBV mutant resistant.

PMID: 14656638 [PubMed - in process]